Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all

摘要

Lung cancer remains the leading cause of cancer related deaths globally (1). Non-small cell lung cancer (NSCLC) accounts for nearly 85% of all lung cancers. The slow progressive decline in both the incidence and mortality from lung cancer in the United States since 2005 is mainly attributable to decreased rates of smoking (2). However, such a trend is yet to be seen worldwide. At the time of diagnosis, 79% of patients present with evidence of regional or distant spread. Overall 5-year survival remains low at 19.4% (3,4). Thus, there are ongoing efforts internationally to improve these outcomes through early detection and screening for lung cancer along with advances in chemotherapy, immunotherapy, stereotactic radiation therapy and targeted therapies (5-7).